FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310093506> ?p ?o ?g. }

• W4310093506 endingPage "416" @default.
• W4310093506 startingPage "415" @default.
• W4310093506 abstract "Patients with multiple relapsed or refractory (R/R) Hodgkin lymphoma (HL) and other CD30+ lymphoma have few effective therapies available and targeted adoptive natural killer (NK) cell immunotherapy is an active area of investigation. Transfer of non-targeted NK cells has shown limited clinical benefit as target recognition of cancers by NK cells remains a substantial barrier. The innate cell engager (ICE®) construct, AFM13, is a first-in-class CD30/CD16A bispecific antibody construct that induces specific and selective killing of CD30+ tumor cells by engaging and activating NK cells. As a single agent, AFM13 has limited clinical activity against HL, likely due to the reduced effector function of autologous NK cells in these patients, which provides the rationale for the combination of AFM13 with allogeneic NK cells. Our prior preclinical work identified a promising combination of cord blood (CB)-derived NK cells that were first IL-12/IL-15/IL-18-preactivated followed by expansion (P+E) with engineered K562 feeder cells expressing membrane-bound IL-21, 4-1BB ligand and CD48 ex vivo, and subsequently complexed with AFM13 just prior to infusion (Kerbauy et al, Clin Cancer Res 2021; 27:3744-56). These cytokine-induced memory-like CB-derived NK cells precomplexed with AFM13 (AFM13-NK) presented chimeric antigen receptor (CAR)-NK cell-like features and showed an increased in vitro and in vivo antitumor activity compared to either P+E NK or AFM13 alone. Building on this work we wished to clinically study adoptive AFM13-NK cell therapy in pts with R/R CD30+ lymphomas. METHODS: This single-center phase I-II trial (NCT04074746) evaluates the safety and activity of AFM13-NK, followed by AFM13 monotherapy. Patients aged 15-75 years with R/R CD30+ lymphomas refractory to brentuximab vedotin are enrolled. The trial goals are to identify the recommended phase 2 dose (RP2D) of AFM13-NK cells, estimate the overall (ORR) and complete response (CR) rates, event-free (EFS) and overall survival (OS) rates, and studies of NK cell activation and persistence. Each treatment cycle consisted of fludarabine/cyclophosphamide (days −5 to −3), followed by infusion of the AFM13-NK cells, cultured for 14 days as described above (day 0), and three weekly IV infusions of AFM13 (200 mg, days 7, 14 and 21). Two cycles were administered to patients 1-19 and 4 cycles were given starting with patient 20. Response was evaluated on day 28 of each cycle. Patients were enrolled at 3 dose levels: DL1 (106 NK/Kg), DL2 (107NK/Kg) and DL3 (108 NK/Kg). Each patient received the same NK dose in all cycles. RESULTS: As of 7/31/22, 30 pts have been enrolled and treated (Table) at DL1 (N=3), DL2 (N=3) and DL3 (N=24), with 1 (N=1), 2 (N=24), 3 (N=3) or 4 cycles (N=3). All patients had active progressive disease at enrollment and no bridging therapy was given. The cords used for each of the 69 cycles were selected with no consideration for HLA match, which was 0/6 (N=31), 1/6 (N=31), 2/6 (N=5), 3/6 (N=1) and 4/6 (N=1). The product infused consisted of >99% NK cells (expanded >2,700 fold), with only 0.02% T cells. The NK cells were >98% viable and 92% of them were bound to AFM13. The products were infused fresh. There were no infusion-related reactions (IRR) after infusing AFM13-NK and 11 IRR in 182 infusions of AFM13 alone (6%) (1 grade 3, 10 grade 2). We saw no cases of CRS, ICANS or GVHD of any grade. DL3 (108 NK/Kg) was established as the RP2D. The ORR in the entire study is 97% with 63% CRs. All 24 patients treated at the RP2D responded (100% ORR) with 70.8% (17/24) CRs. Five patients had a response consolidated with a SCT. At median follow-up of 8 (range 1-23) months, the EFS and OS rates of all 30 patients are 57% and 83%, respectively. AFM-NK cells were detected in serum from day 1 post infusion and persisted for 3-4 weeks. Donor NK levels followed similar patterns after each cycle, which argues against a sensitization effect in the patient after the first NK infusion. Donor NK cells showed by CyTOF increased binding to AFM13 and expression of activation markers. CONCLUSIONS: This is the first clinical trial to date using an ICE® construct precomplexed with cytokine-induced memory-like CB-NK cells to treat patients with CD30+ R/R HL and NHL. Our preliminary results indicate that this ICE® precomplexed CB-NK cell therapy has an excellent tolerability profile and is highly active in patients with heavily pretreated R/R CD30+ lymphomas and warrants further investigation. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310093506 created "2022-11-30" @default.
• W4310093506 creator A5009162219 @default.
• W4310093506 creator A5013086162 @default.
• W4310093506 creator A5016927735 @default.
• W4310093506 creator A5022871468 @default.
• W4310093506 creator A5023203245 @default.
• W4310093506 creator A5024602252 @default.
• W4310093506 creator A5025853189 @default.
• W4310093506 creator A5026334708 @default.
• W4310093506 creator A5027071793 @default.
• W4310093506 creator A5029237145 @default.
• W4310093506 creator A5032622792 @default.
• W4310093506 creator A5033999259 @default.
• W4310093506 creator A5037077714 @default.
• W4310093506 creator A5038619722 @default.
• W4310093506 creator A5040118784 @default.
• W4310093506 creator A5043199504 @default.
• W4310093506 creator A5045738854 @default.
• W4310093506 creator A5050962913 @default.
• W4310093506 creator A5055885795 @default.
• W4310093506 creator A5061740256 @default.
• W4310093506 creator A5066625407 @default.
• W4310093506 creator A5075134379 @default.
• W4310093506 creator A5075872357 @default.
• W4310093506 date "2022-11-15" @default.
• W4310093506 modified "2023-09-30" @default.
• W4310093506 title "Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma" @default.
• W4310093506 doi "https://doi.org/10.1182/blood-2022-156125" @default.
• W4310093506 hasPublicationYear "2022" @default.
• W4310093506 type Work @default.
• W4310093506 citedByCount "4" @default.
• W4310093506 countsByYear W43100935062023 @default.
• W4310093506 crossrefType "journal-article" @default.
• W4310093506 hasAuthorship W4310093506A5009162219 @default.
• W4310093506 hasAuthorship W4310093506A5013086162 @default.
• W4310093506 hasAuthorship W4310093506A5016927735 @default.
• W4310093506 hasAuthorship W4310093506A5022871468 @default.
• W4310093506 hasAuthorship W4310093506A5023203245 @default.
• W4310093506 hasAuthorship W4310093506A5024602252 @default.
• W4310093506 hasAuthorship W4310093506A5025853189 @default.
• W4310093506 hasAuthorship W4310093506A5026334708 @default.
• W4310093506 hasAuthorship W4310093506A5027071793 @default.
• W4310093506 hasAuthorship W4310093506A5029237145 @default.
• W4310093506 hasAuthorship W4310093506A5032622792 @default.
• W4310093506 hasAuthorship W4310093506A5033999259 @default.
• W4310093506 hasAuthorship W4310093506A5037077714 @default.
• W4310093506 hasAuthorship W4310093506A5038619722 @default.
• W4310093506 hasAuthorship W4310093506A5040118784 @default.
• W4310093506 hasAuthorship W4310093506A5043199504 @default.
• W4310093506 hasAuthorship W4310093506A5045738854 @default.
• W4310093506 hasAuthorship W4310093506A5050962913 @default.
• W4310093506 hasAuthorship W4310093506A5055885795 @default.
• W4310093506 hasAuthorship W4310093506A5061740256 @default.
• W4310093506 hasAuthorship W4310093506A5066625407 @default.
• W4310093506 hasAuthorship W4310093506A5075134379 @default.
• W4310093506 hasAuthorship W4310093506A5075872357 @default.
• W4310093506 hasBestOaLocation W43100935061 @default.
• W4310093506 hasConcept C203014093 @default.
• W4310093506 hasConcept C2779338263 @default.
• W4310093506 hasConcept C502942594 @default.
• W4310093506 hasConcept C70905583 @default.
• W4310093506 hasConcept C71924100 @default.
• W4310093506 hasConcept C86803240 @default.
• W4310093506 hasConceptScore W4310093506C203014093 @default.
• W4310093506 hasConceptScore W4310093506C2779338263 @default.
• W4310093506 hasConceptScore W4310093506C502942594 @default.
• W4310093506 hasConceptScore W4310093506C70905583 @default.
• W4310093506 hasConceptScore W4310093506C71924100 @default.
• W4310093506 hasConceptScore W4310093506C86803240 @default.
• W4310093506 hasIssue "Supplement 1" @default.
• W4310093506 hasLocation W43100935061 @default.
• W4310093506 hasOpenAccess W4310093506 @default.
• W4310093506 hasPrimaryLocation W43100935061 @default.
• W4310093506 hasRelatedWork W1911134467 @default.
• W4310093506 hasRelatedWork W1993312964 @default.
• W4310093506 hasRelatedWork W2079532092 @default.
• W4310093506 hasRelatedWork W2118749583 @default.
• W4310093506 hasRelatedWork W2139644163 @default.
• W4310093506 hasRelatedWork W2171905452 @default.
• W4310093506 hasRelatedWork W2411077793 @default.
• W4310093506 hasRelatedWork W2793633348 @default.
• W4310093506 hasRelatedWork W2981634038 @default.
• W4310093506 hasRelatedWork W4239792933 @default.
• W4310093506 hasVolume "140" @default.
• W4310093506 isParatext "false" @default.
• W4310093506 isRetracted "false" @default.
• W4310093506 workType "article" @default.